Sichuan Kelun Pharmaceutical (002422) 44th Annual J.P. Morgan Healthcare Conference summary

Company overview and strategy

• Focuses on innovative drug R&D in oncology, immunology, metabolism, and other diseases, leveraging a differentiated OptiDC drug-conjugate platform.

• Operates over 30 pipeline programs, with four approved products and two at the NDA stage, and expects more approvals and label expansions in 2026.

• Employs around 2,000 staff, with significant R&D, manufacturing, and commercial teams.

• Strategic partnerships with global firms like MSD, Ellipses, Windward Bio, and Crescent Bio to maximize pipeline and corporate value.

• Expanding commercialization capabilities and global reach, with a focus on ex-China markets.

Pipeline highlights and clinical progress

• Four launched products include TROP2 ADC (sac-TMT), HER2-ADC, Cetuximab N01, and PD-L1, with a next-generation RET inhibitor at NDA stage.

• TROP2 ADC sac-TMT approved for three indications in China, including first global approval for lung cancer treatment.

• HER2-ADC approved for HER2-positive breast cancer, showing significant PFS and ORR improvements over T-DM1.

• Multiple pivotal clinical studies underway for breast, lung, and GI cancers, with additional phase I/II programs advancing.

• Clinical data presented at major conferences and published in top journals, including ESMO and NEJM.

Commercialization and market access

• Three core products included in China's NRDL 2025, enhancing reimbursement and market access.

• Full-fledged commercialization team established, covering all Class III hospitals and key opinion leaders.

• Indication concentration in BC, LC, and GI cancers creates marketing synergies.